Boehringer Ingelheim launches Phase 3 study for novel IPF therapy

Currently, there are only two FDA-approved drugs for idiopathic pulmonary fibrosis (IPF) — Ofev (nintedanib) from Boehringer Ingelheim and Esbriet (pirfenidone) from Genentech.

Now, Boehringer Ingelheim is announcing the launch of the global FIBRONEER-IPF study focused on BI 1015550, an experimental phosphodiesterase 4B (PDE4B) inhibitor, in idiopathic pulmonary fibrosis (IPF).

The study is part of a broader FIBRONEER program that includes FIBRONEER-ILD for progressive fibrosing interstitial lung diseases.

FDA has granted Orphan Drug Designation to BI 1015550 in IPF.

The prognosis for patients diagnosed with IPF tends to be poor.

Boehringer Ingelheim discovered that the BI 1015550 had anti-fibrotic effects in preclinical and lung fibrosis cellular models.

In the 1990s, Schering helped forge a path for BI 1015550 by developing a selective phosphodiesterase-4 inhibitor known as Rolipram as a possible antidepressant.

Boehringer I…

Read more
  • 0